Abstract：
UNASSIGNED: This study aimed to assess the effectiveness of monocular and bilateral injections of Dexamethasone-21-acetate (Dex-21-Ac) into the murine fornix twice a week as a glucocorticoid-induced ocular hypertension model and investigated potential systemic side effects.
UNASSIGNED: Dex-21-Ac was administered twice weekly in three groups: bilateral injections, monocular injections, and a control group receiving the vehicle solution bilateral. After 21 days, enucleated eyes were examined using immunocytochemistry (ICC), and organ histology was performed.
UNASSIGNED: All groups receiving Dex-21-Ac injections had a significant increase in intraocular pressure (IOP). Monocular injections also resulted in a significant increase in IOP in the fellow eye. The Dex-21-Ac-treated groups showed a bilateral increase in IOP of approximately 8 mmHg, accompanied by elevated expression of alpha smooth muscle actin and fibronectin in the anterior chamber angle. There were no significant changes in weight progression. Hepatic steatosis was observed in all Dex-21-Ac-treated animals, and some suffered from residual neuromuscular blockade under fentanyl anesthesia.
UNASSIGNED: Bilateral injections of Dex-21-Ac twice a week lead to a significant increase in daytime IOP and fibrotic changes in the trabecular meshwork. Unilateral application has a significant impact on the fellow eye. Local dexamethasone leads to notable systemic effects independent of changes in animal weight. Considering liver damage and associated influence on metabolization, hepatically eliminated injection anesthetics may lead to overdosing and are not recommended. They should be replaced by inhalation anesthesia.
UNASSIGNED: Dex-21-Ac was administered twice weekly in three groups: bilateral injections, monocular injections, and a control group receiving the vehicle solution bilateral. After 21 days, enucleated eyes were examined using immunocytochemistry (ICC), and organ histology was performed.
UNASSIGNED: All groups receiving Dex-21-Ac injections had a significant increase in intraocular pressure (IOP). Monocular injections also resulted in a significant increase in IOP in the fellow eye. The Dex-21-Ac-treated groups showed a bilateral increase in IOP of approximately 8 mmHg, accompanied by elevated expression of alpha smooth muscle actin and fibronectin in the anterior chamber angle. There were no significant changes in weight progression. Hepatic steatosis was observed in all Dex-21-Ac-treated animals, and some suffered from residual neuromuscular blockade under fentanyl anesthesia.
UNASSIGNED: Bilateral injections of Dex-21-Ac twice a week lead to a significant increase in daytime IOP and fibrotic changes in the trabecular meshwork. Unilateral application has a significant impact on the fellow eye. Local dexamethasone leads to notable systemic effects independent of changes in animal weight. Considering liver damage and associated influence on metabolization, hepatically eliminated injection anesthetics may lead to overdosing and are not recommended. They should be replaced by inhalation anesthesia.
摘要：
■本研究旨在评估每周两次将地塞米松-21-乙酸酯(Dex-21-Ac)单眼和双侧注射入小鼠穹窿作为糖皮质激素诱导的高眼压模型的有效性,并研究潜在的全身副作用。
■Dex-21-Ac在三组中每周两次：双侧注射，单眼注射,和对照组接收车辆解决方案双边。21天后,使用免疫细胞化学（ICC）检查摘除的眼睛，并进行了器官组织学检查。
■接受Dex-21-Ac注射的所有组的眼内压（IOP）均显着增加。单眼注射还导致对眼中IOP的显著增加。Dex-21-Ac治疗组显示双侧IOP增加约8mmHg，伴随着α平滑肌肌动蛋白和纤连蛋白在前房角的表达升高。体重进展没有显著变化。在所有Dex-21-Ac处理的动物中观察到肝脂肪变性,有些人在芬太尼麻醉下患有残留的神经肌肉阻滞。
■每周两次双侧注射Dex-21-Ac会导致白天IOP的显着增加和小梁网的纤维化变化。单侧应用对同伴眼睛有重大影响。局部地塞米松导致明显的全身效应，而与动物体重的变化无关。考虑到肝脏损害和对代谢的相关影响，消除注射麻醉药可能导致药物过量，不建议使用。它们应该用吸入麻醉代替。
■Dex-21-Ac在三组中每周两次：双侧注射，单眼注射,和对照组接收车辆解决方案双边。21天后,使用免疫细胞化学（ICC）检查摘除的眼睛，并进行了器官组织学检查。
■接受Dex-21-Ac注射的所有组的眼内压（IOP）均显着增加。单眼注射还导致对眼中IOP的显著增加。Dex-21-Ac治疗组显示双侧IOP增加约8mmHg，伴随着α平滑肌肌动蛋白和纤连蛋白在前房角的表达升高。体重进展没有显著变化。在所有Dex-21-Ac处理的动物中观察到肝脂肪变性,有些人在芬太尼麻醉下患有残留的神经肌肉阻滞。
■每周两次双侧注射Dex-21-Ac会导致白天IOP的显着增加和小梁网的纤维化变化。单侧应用对同伴眼睛有重大影响。局部地塞米松导致明显的全身效应，而与动物体重的变化无关。考虑到肝脏损害和对代谢的相关影响，消除注射麻醉药可能导致药物过量，不建议使用。它们应该用吸入麻醉代替。
